GlassScriptPhysician profile
Donny Hardy
NPI 1811981533
$1,158.58
in general payments reported to CMS, 2019-2025
20 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $85.06 · 2022: $30.53 · 2023: $98.03 · 2024: $190 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $164.56 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $132.56 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $104.96 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $96.66 | 2019-2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $91.61 | 2019-2025 | Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.46 | 2019-2025 | Xifaxan |
| Abbvie INC. | $64.81 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.74 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.61 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $44.34 | 2019-2025 | Mounjaro |
| Janssen Pharmaceuticals, INC | $38.52 | 2019 | |
| Amgen INC. | $35.44 | 2019 | |
| Exact Sciences Corporation | $35.12 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $30.42 | 2019 | |
| Dexcom, INC. | $30.22 | 2024 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $24.34 | 2019 | |
| Axsome Therapeutics, INC. | $21.12 | 2025 | Auvelity |
| Insulet Corporation | $19.65 | 2025 | Omnipod |
| Esperion Therapeutics, INC. | $15.46 | 2025 | Nexletol |
| Abiomed | $14.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donny Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.